. 2014 Sep 15;35(10):1265–1273. doi: 10.1038/aps.2014.72

Table 2. Significant alterations of endogenous metabolites detected by GC-MS. ^bP<0.05, ^cP<0.01 vs normal control group. ^eP<0.05, ^fP<0.01 vs model control group. ^hP<0.05, ⁱP<0.01 vs fenofibrate-treatment group.

Metabolites	Biological role	Fold change
Metabolites	Biological role	A	B	C	D
Linoleic acid	An important role in the pathogenesis of essential hypertension	0.67^b	1.36^e	1.76^f	0.77^h
Cholesterol	Biomarker of hyperlipidemia	5.82^b	0.54^f	0.39^f	1.40^h
Alanine	An metabolic intermediate in both glycolysis and gluconeogenesis	0.89	0.36^f	0.95	0.38ⁱ
Valine		0.96	0.48^f	0.70^e	0.68^h
Isoleucine	Essential amino acids, stress, energy and muscle metabolism	0.39^c	0.43^e	0.46^e	0.94
Proline	Non-essential amino acid synthesized from glutamic acid	1.26^b	0.64^e	0.38^f	1.65ⁱ
Phenylalanine	An essential amino acid and the precursor for the amino acid tyrosine	0.97	0.58^e	0.91	0.64^h
Ornithine	Amino acid produced in the urea cycle from arginine	3.00^c	0.30^f	0.44^f	0.68^h
Tyrosine	A precursor for epinephrine	0.67^c	0.98	1.36^e	0.72^h
Glycine		0.97	1.03	1.27	0.81^h
Myo-Inositol	A crucial role in the phosphatidylinositol signaling pathway	0.93	0.72^e	0.45^f	1.59^h
β-Hydroxybutyric acid	A four-carbon fatty acid	1.98	0.24^f	0.27^f	0.90
Creatinine	An indicator of renal function; A breakdown product of creatine phosphate in muscle	4.46^c	0.11^f	0.29^f	0.37ⁱ
Glutamine	A key molecule in cellular metabolism, γ-glutamyl cycle	0.94	0.61^f	0.74^e	0.82^h
Citric acid	Tricarboxylic acid cycle	0.59^c	1.02	0.64^f	1.58^h
D-glucose	Primary source of energy, available from glycogenolysis and gluconeogenesis or food	0.99	1.31^e	1.32^e	0.99
D-Sorbit		1.53^c	0.81^e	0.84^e	0.96
Mannose	An important roles in protein quality control	0.53^c	0.28^f	0.99	0.28ⁱ
Galactose	Component of glycerolipid and glycosphingolipid metabolism	1.24	0.59^f	0.54^f	1.10

A: Ratio of abundance of metabolites in plasma samples between diet-induced hyperlipidemia group and normal control group at week 6.

B: Ratio of abundance of metabolites in plasma samples between simvastatin-treatment group and model control group at week 6.

C: Ratio of abundance of metabolites in plasma samples between fenofibrate-treatment group and model control group at week 6.

D: Ratio of abundance of metabolites in plasma samples between simvastatin-treatment group and fenofibrate-treatment group at week 6.

Table 2. Significant alterations of endogenous metabolites detected by GC-MS. bP<0.05, cP<0.01 vs normal control group. eP<0.05, fP<0.01 vs model control group. hP<0.05, iP<0.01 vs fenofibrate-treatment group.

Table 2. Significant alterations of endogenous metabolites detected by GC-MS. ^bP<0.05, ^cP<0.01 vs normal control group. ^eP<0.05, ^fP<0.01 vs model control group. ^hP<0.05, ⁱP<0.01 vs fenofibrate-treatment group.